Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
22.68
+1.12 (5.19%)
At close: Jul 30, 2026, 4:00 PM EDT
22.90
+0.22 (0.97%)
After-hours: Jul 30, 2026, 7:34 PM EDT
Monte Rosa Therapeutics Revenue
Monte Rosa Therapeutics had revenue of $4.21M in the quarter ending March 31, 2026, a decrease of -95.04%. This brings the company's revenue in the last twelve months to $42.95M, down -73.07% year-over-year. In the year 2025, Monte Rosa Therapeutics had annual revenue of $123.67M with 63.54% growth.
Revenue (ttm)
$42.95M
Revenue Growth
-73.07%
P/S Ratio
44.61
Revenue / Employee
$229,695
Employees
187
Market Cap
1.92B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 123.67M | 48.05M | 63.54% |
| Dec 31, 2024 | 75.62M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurinia Pharmaceuticals | 298.30M |
| UroGen Pharma | 140.49M |
| Agios Pharmaceuticals | 98.34M |
| Mesoblast | 65.38M |
| Ocular Therapeutix | 52.04M |
| Nanobiotix | 38.27M |
| Stoke Therapeutics | 32.08M |
| Taysha Gene Therapies | 7.47M |
GLUE News
- 3 days ago - Monte Rosa Therapeutics price target raised to $40 from $30 at Jefferies - TheFly
- 4 weeks ago - Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Monte Rosa Therapeutics price target raised, named a ‘top pick’ at Guggenheim - TheFly
- 2 months ago - Monte Rosa Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Monte Rosa Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 2 months ago - Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics price target raised to $31 from $30 at JPMorgan - TheFly
- 3 months ago - Monte Rosa Therapeutics reports Q1 revenue $4.21M, consensus $11.39M - TheFly